0000000000759067

AUTHOR

Pascal Chavanet

showing 24 related works from this author

Prophylactic Fluconazole andCandida kruseiInfections

1992

biologybusiness.industryCandida kruseimedicineGeneral Medicinebiology.organism_classificationbusinessFluconazoleMicrobiologymedicine.drugNew England Journal of Medicine
researchProduct

The Respect of Recommendations Provided in an International Travelers' Medical Service: Far From the Cup to the Lips

2013

Equipe plutôt EA Pôle MERS CT3 EJ3; Background: It is not clearly known how frequently the recommendations given to travelers are followed, and what factors could encourage compliance with these recommended measures. Methods: Adults consulting at a Medical Department for International Travelers (International Travelers' Medical Services, ITMS) in October and November 2010 were asked to answer a questionnaire before their journey. They were also contacted for a post-travel telephone interview to determine whether they had followed the recommendations regarding vaccinations and malaria prevention, and the reasons for poor or noncompliance with these recommendations. Results A total of 353 tra…

Adultmedicine.medical_specialtyPediatricsMultivariate analysisprévention conseil[SDV]Life Sciences [q-bio]MEDLINEDirective CounselingChemopreventionAntimalarialsRisk FactorsSurveys and QuestionnairesHealth careOutcome Assessment Health CarePreventive Health ServicesMedicineTravel medicineHumans[SDV.BV]Life Sciences [q-bio]/Vegetal BiologyMedical prescriptionTravelMosquito Netsbusiness.industryVaccinationGeneral MedicineMiddle AgedMalariaTelephone interviewSocioeconomic FactorsFamily medicineChemoprophylaxis[SDE]Environmental SciencesMosquito netPatient ComplianceFemaleFrancebusinesshuman activitiesTravel Medicine
researchProduct

Vitamin D supplementation, bone turnover, and inflammation in HIV-infected patients

2018

IF 1.307 (2017); International audience; ObjectiveTo assess whether vitamin D supplementation could be associated with a modification of inflammatory markers and bone turnover in HIV-1-infected patients.Patients and methodsPatients who participated in an initial survey in 2010 and who were followed in the same department were included in a new study in 2012. Between 2010 and 2012, vitamin D supplementation was offered to patients presenting with hypovitaminosis D as per appropriate guidelines. Clinical examinations were performed, and fasting blood samples were taken for inflammation and bone marker evaluations.ResultsOf the 263 patients who participated in the 2010 study, 198 were included…

AdultMale0301 basic medicinemedicine.medical_specialtyHypovitaminose DHIV InfectionsInflammationGastroenterologyBone remodeling03 medical and health sciences0302 clinical medicineHypovitaminosisN-terminal telopeptideTraitement antirétroviral[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicinemedicineVitamin D and neurologyHumansHiv infected patientsLongitudinal StudiesProspective Studies030212 general & internal medicineVitamin DInflammationVitamin d supplementationbusiness.industryHIVHypovitaminosis DVIHMiddle AgedVitamin D Deficiency16. Peace & justice030112 virologyAntiretroviral therapy3. Good healthInfectious DiseasesDietary SupplementsVitamine DFemaleBone Remodelingmedicine.symptombusinessBone markerMédecine et Maladies Infectieuses
researchProduct

In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneum…

2008

In this study, we compared the efficacy of ceftazidime (CAZ) intermittent versus continuous infusion with or without tobramycin (TOB) for the treatment of pneumonia caused by Pseudomonas aeruginosa in rabbits. Treatments were humanised and mimicked intermittent CAZ (iCAZ) (2g three times daily), continuous CAZ (cCAZ) (4g once daily (qd)) and TOB (10mg/kg qd). Minimum inhibitory concentrations (MICs) were 1mg/L and 4mg/L for TOB and CAZ, respectively. Bacterial efficacy in lungs was as follows: control, 9+/-0.6 colony-forming units (CFU)/g; TOB monotherapy, 8+/-0.5CFU/g; iCAZ monotherapy, 7.8+/-1.4CFU/g; cCAZ monotherapy, 8+/-0.4CFU/g (P = 0.005); and iCAZ+TOB, 8+/-0.5CFU/g; cCAZ+TOB, 7.2+/-…

Microbiology (medical)Malemedicine.drug_classAntibioticsColony Count MicrobialCeftazidimeMicrobial Sensitivity TestsCeftazidimeMicrobiologyPseudomonas infectionmedicineTobramycinPneumonia BacterialAnimalsHumansPharmacology (medical)Pseudomonas InfectionsInfusions IntravenousLungAntibacterial agentProtein synthesis inhibitorbusiness.industryAminoglycosideGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesPharmacodynamicsTobramycinDrug Therapy CombinationRabbitsbusinessSpleenmedicine.drugInternational journal of antimicrobial agents
researchProduct

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

2017

International audience; Background: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis. Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile.Objectives: To compare the in vivo activity of levofloxacin and moxifloxacin against M. tuberculosis strains with various levels of fluoroquinolone resistance.Methods: BALB/c mice were intravenously infected with 106M. tuberculosis H37Rv and three isogenic mutants: GyrA A90V, GyrB E540A and GyrB A543V. Treatment with 50 or 100 mg/kg levofloxacin and 60 or 66 mg/kg moxifloxacin was given orally every 6 h, for 4 we…

0301 basic medicineMicrobiology (medical)Tuberculosis[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationmiceExtensively Drug-Resistant Tuberculosis030106 microbiologyMicrobial Sensitivity TestsMicrobiologyMycobacterium tuberculosis03 medical and health sciences0302 clinical medicine[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationLevofloxacinMoxifloxacinIn vivo[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineAnimalsPharmacology (medical)heterocyclic compounds030212 general & internal medicinePharmacologyMice Inbred BALB ClevofloxacinbiologyChemistry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationExtensively drug-resistant tuberculosisMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationbacterial infections and mycosesFluoroquinolone resistanceAnti-Bacterial Agents3. Good health[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesDisease Models AnimalSafety profileTreatment OutcomeInfectious Diseasestuberculosis[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesbacteriamoxifloxacinFluoroquinolonesmedicine.drug
researchProduct

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.

2011

SUMMARYOptimal antiretroviral strategies for HIV-infected patients still need to be established. To this end a decision tree including different antiretroviral strategies that could be adopted for HIV-infected patients was built. A 10-year follow-up was simulated by using transitional probabilities estimated from a large cohort using a time-homogeneous Markov model. The desired outcome was for patients to maintain a CD4 cell count of >500 cells/mm3without experiencing AIDS or death. For patients with a baseline HIV viral load ⩾5 log10copies/ml, boosted protease inhibitor-based immediate highly active antiretroviral therapy (HAART) allowed them to spend 12% more time with CD4 ⩾500/mm3than…

AdultMalemedicine.medical_specialty[ INFO ] Computer Science [cs]EpidemiologyAnti-HIV AgentsDecision treeHIV InfectionsDrug Administration ScheduleCohort Studies03 medical and health sciences0302 clinical medicineLife ExpectancyAcquired immunodeficiency syndrome (AIDS)Internal medicineAntiretroviral Therapy Highly ActiveHiv infected patientsMedicineHumansProtease inhibitor (pharmacology)In patient[INFO]Computer Science [cs]Computer Simulation030212 general & internal medicineCd4 cell countComputingMilieux_MISCELLANEOUS0303 health sciences030306 microbiologybusiness.industryDecision TreesMiddle AgedViral Loadmedicine.diseaseAntiretroviral therapyMarkov Chains3. Good healthCD4 Lymphocyte CountInfectious DiseasesTreatment OutcomeImmunologyDisease ProgressionFemalebusinessViral loadFollow-Up StudiesEpidemiology and infection
researchProduct

A New Prognosis Score to Predict Mortality After Acute Pneumonia in Very Elderly Patients

2016

International audience; Objectives: Acute pneumonia (AP) induces an excess of mortality among the elderly. We evaluated the value of a new predictive biomarker index compared to usual prognosis scores for predicting in-hospital and 1-year mortalities in elderly inpatients with AP.Design: Retrospective study in 6 clinical departments of a university hospital.Setting: Burgundy university hospital (France).Participants: All patients aged 75 and over with AP and hospitalized between January 1 and June 30, 2013, in the departments of medicine (5) and intensive care (1) of our university hospital.Measurements: A new index, which we named UBMo, was created by multiplying the uremia (U in the formu…

Malecommunity-acquired pneumoniaPneumonia severity indexseveritysepsis0302 clinical medicineElderlyadultsscoreHospital Mortality030212 general & internal medicineProspective cohort studyGeneral NursingAged 80 and overvalidation[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyHealth PolicyMortality rateGeneral Medicinecohort3. Good healthAcute DiseaseFemaleFranceterm survivalmanagementmedicine.medical_specialtyhospitalized-patients[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology03 medical and health sciencesPredictive Value of TestsIntensive careInternal medicinemedicineHumanspneumoniaIntensive care medicineAgedRetrospective Studiesbusiness.industrybiomarkersRetrospective cohort studymedicine.diseasemortalityUremiaPneumoniaBlood pressure030228 respiratory systemprognosisGeriatrics and Gerontologybusiness
researchProduct

Mild-stretch mechanical ventilation upregulates toll-like receptor 2 and sensitizes the lung to bacterial lipopeptide.

2011

Introduction Mechanical ventilation (MV) could prime the lung toward an inflammatory response if exposed to another insult such as bacterial invasion. The underlying mechanisms are not so far clear. Toll-like receptors (TLRs) allow the host to recognize selectively bacterial pathogens and in turn to trigger an immune response. We therefore hypothesized that MV modulates TLR2 expression and in turn modifies responsiveness to agonists such as bacterial lipopeptide (BLP). Method Both in vitro and in vivo experiments were conducted. First, TLR2 expression and protein were measured in the A549 pulmonary epithelial cell line submitted to 8-hour cyclic stretch (20% elongation; 20/minute rate). Aft…

MaleInterleukin-6/metabolismCell Culture TechniquesRespiration Artificial/methodsBiologyLung injuryCritical Care and Intensive Care MedicineReal-Time Polymerase Chain Reaction03 medical and health scienceschemistry.chemical_compoundLipopeptidesToll-Like Receptor 2/analysis/genetics/metabolism0302 clinical medicineImmune systemLipopeptides/metabolismDownregulation and upregulationAnimalsReceptorLung030304 developmental biologyddc:616A549 cell0303 health sciencesToll-like receptorEpithelial Cells/metabolism/microbiologyddc:617BacteriaInterleukin-6ResearchInterleukin-8Lipopeptide030208 emergency & critical care medicineEpithelial CellsSequence Analysis DNArespiratory systemFlow CytometryRespiration ArtificialLung/immunology/metabolismToll-Like Receptor 23. Good healthCell biologyUp-RegulationTLR2chemistryInterleukin-8/metabolismBacteria/metabolismImmunologyRabbitsCritical care (London, England)
researchProduct

Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors

2005

BACKGROUND:The substitution of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) for protease inhibitors (PIs) has demonstrated its suitability to maintain virologic response. However, the switch from PIs to an NNRTI could fail for a number of reasons, including NNRTI-associated toxicity and emergence of NNRTI-resistant variants.OBJECTIVE:To describe the virologic failures among 74 HIV-infected patients who switched from PIs to nevirapine.METHODS:Virologic failure was defined as any rebound of the plasma HIV-RNA (pVL) levels >1000 copies/mL on one occasion or 2 consecutive intermittent viremia episodes defined as increases of the pVL >20 copies/mL but <1000 copies/mL. Virolog…

AdultMaleNevirapineHIV InfectionsViremiaImmunopathologyDrug Resistance ViralHumansMedicinePharmacology (medical)Protease inhibitor (pharmacology)NevirapineProspective StudiesSidabiologyReverse-transcriptase inhibitorbusiness.industryHIV Protease InhibitorsMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseVirologyToxicityHIV-1FemaleViral diseasebusinessFollow-Up Studiesmedicine.drugAnnals of Pharmacotherapy
researchProduct

Generic vancomycin products: Analysis of serum concentrations in patients with acute myeloid leukemia.

2013

Summary Concerns have recently emerged about the quality of generic vancomycin products. Our aim is to analyze serum vancomycin concentrations measured 48 hours after the start of an empirical treatment regimen in patients with acute myeloid leukemia (AML) who received one of the two generic vancomycin products available in France. Patients and methods Seventy-nine AML patients treated with vancomycin during two study periods were included in the study. Our vancomycin dosing regimen was based on the patients’ total body weight adjusted for renal clearance. Results A total of 93 serum vancomycin concentrations were collected: 31 in period 1 and 62 in period 2. In bivariate analysis, the mean…

AdultMalemedicine.medical_specialtyAdolescentPharmaceutical ScienceKidneyGastroenterologyYoung AdultVancomycinInternal medicinemedicineDrugs GenericHumansIn patientGeneric ProductAgedRetrospective StudiesPharmacologybusiness.industryMyeloid leukemiaSerum concentrationMiddle AgedAnti-Bacterial AgentsRegimenLeukemia Myeloid AcuteImmunologyVancomycinFemaleHemoglobinbusinessmedicine.drugClearanceAnnales pharmaceutiques francaises
researchProduct

Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain

2019

IF 5.217; International audience; BackgroundOwing to its antibacterial properties, ceftaroline could be attractive for prevention or treatment of bacterial post-neurosurgical meningitis/ventriculitis. However, few data are available concerning its meningeal concentrations.ObjectivesTo investigate ceftaroline CSF pharmacokinetics in ICU patients with an external ventricular drain (EVD).MethodsPatients received a single 600 mg dose of ceftaroline as a 1 h intravenous infusion. Blood and CSF samples were collected before and 0.5, 1, 3, 6, 12 and 24 h after the end of the infusion. Concentrations were assayed in plasma and CSF by LC–MS/MS. A two-step compartmental pharmacokinetic analysis was c…

Male0301 basic medicinemedicine.medical_treatmentprotein bindinginfusion proceduresintensive care unitCerebral VentriclesCerebral VentriculitisPostoperative Complications0302 clinical medicineCerebrospinal fluidTandem Mass SpectrometryPharmacology (medical)030212 general & internal medicineInfusions Intravenousintravenous infusion proceduresmeningitisMiddle AgedAnti-Bacterial Agents3. Good healthIntensive Care UnitsInfectious DiseasesAnesthesiaDrainageceftarolineFemalepharmacokineticsMeningitisAdultMicrobiology (medical)VentriculostomyAdolescent030106 microbiologyCmax[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgerycerebrospinal fluidMeningitis BacterialYoung Adult03 medical and health sciencesPharmacokineticsavian ventriculitismedicineVentriculitisHumansDistribution (pharmacology)plasmaAgedbacterial post-neurosurgical meningitis/ventriculitisPharmacologybusiness.industryModels Theoreticalmedicine.diseaseneurosurgical proceduresCephalosporinsventriculostomybusinessChromatography LiquidExternal ventricular drainJournal of Antimicrobial Chemotherapy
researchProduct

Emergence of tularemia in France: paradigm of the Burgundy region

2011

International audience; We report three consecutive cases of tularemia occurring in Burgundy, France, a region previously considered not endemic for tularemia. The patients presented with varied and unspecific clinical manifestations. The epidemiological circumstances, especially the mode of contamination, were not particularly suggestive of tularemia. Serological diagnosis was delayed in two cases because of the lack of significant antibody titers at the time of admission. In contrast, a diagnosis could readily be obtained in all three cases by detection of Francisella tularensis DNA from clinical samples using PCR-based methods. These cases highlight the increased incidence and geographic…

MaleEpidemiologyMESH: Lymph NodesCommunicable Diseases EmergingSerologyTularemia0302 clinical medicineMESH: Early DiagnosisEpidemiologyDiagnosisMESH: Communicable Diseases Emerging030212 general & internal medicineMESH: DoxycyclineFrancisella tularensisTularemia0303 health sciencesMESH: TularemiaMESH: Middle AgedbiologyMESH: Real-Time Polymerase Chain ReactionIncidence (epidemiology)[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]Antibody titerGeneral Medicinerespiratory systemMiddle Aged3. Good healthAnti-Bacterial AgentsInfectious DiseasesFrancisella tularensis DNADoxycyclineFemaleFranceFluoroquinolonesAdultDNA BacterialMicrobiology (medical)medicine.medical_specialtyReal-Time Polymerase Chain Reactioncomplex mixtures03 medical and health sciencesMESH: Francisella tularensisMESH: Anti-Bacterial AgentsmedicineHumansFrancisella tularensisMESH: Humans030306 microbiologyMESH: AdultMESH: Fluoroquinolonesbiology.organism_classificationmedicine.diseasebacterial infections and mycosesVirologyMESH: DNA BacterialMESH: MaleMESH: FranceEarly DiagnosisbacteriaLymph NodesMESH: FemaleReal-time PCRInternational Journal of Infectious Diseases
researchProduct

Successful control of a Methicillin-resistant Staphylococcus aureus outbreak in a neonatal intensive care unit: a retrospective, before-after study

2013

International audience; Background : Aim of this study was to provide a detailed description of a Methicillin-resistant Staphylococcus aureus (MRSA) outbreak management strategy in the neonatal intensive care unit of a university hospital.MethodsThis was a retrospective, “before-after” study, over two consecutive 18-month periods. The outbreak management strategy was performed by a multidisciplinary team and included: extensive healthcare workers (HCW) involvement, education, continuous hand-hygiene training and active MRSA colonization surveillance. The actions implemented were identified based on an anonymous, voluntary, reporting system, carried out among all the HCW, and regular audit a…

MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyNeonatal intensive care unitQuality-improvementVoice BundleCommunity030501 epidemiology[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsStaphylococcal infectionsmedicine.disease_causeInfant Newborn Diseases03 medical and health sciencesEndemic0302 clinical medicineMedical microbiologyPractices030225 pediatricsIntensive Care Units NeonatalHospital-acquired infectionmedicinePérinatalitéHumansIntensive care medicineRetrospective StudiesCross Infectionbusiness.industryInfant NewbornOutbreakInfantRetrospective cohort studybiochemical phenomena metabolism and nutritionStaphylococcal Infectionsbacterial infections and mycosesmedicine.diseaseNewbornMethicillin-resistant Staphylococcus aureusHospital-acquired infection3. Good healthInfectious DiseasesStaphylococcus aureusFemaleMethicillin ResistanceFrance0305 other medical sciencebusinessResearch Article
researchProduct

Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study

2016

International audience; Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyStaphylococcus aureusmedicine.drug_class030106 microbiologyAntibioticsBacteremiaPenicillinsPrognostic factorsTertiary Care Centers03 medical and health sciencesInterquartile range[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinInternal medicineCase fatality ratemedicineHumansBlood cultureProspective StudiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedAntistaphylococcal penicillinsCross Infectionmedicine.diagnostic_testbusiness.industrySeptic shockGeneral MedicineMiddle AgedStaphylococcal Infectionsmedicine.diseasePrognosisSurvival Analysis3. Good healthSurgeryInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinBacteraemiaAntistaphylococcal penicillinFemaleFrancebusinessmedicine.drug
researchProduct

Prevalence and incidence of kidney diseases leading to hospital admission in people living with HIV in France: an observational nationwide study.

2019

ObjectivesTo describe hospitalisations for kidney disease (KD) among people living with HIV (PLHIV) in France and to identify the factors associated with such hospitalisations since data on the epidemiology of KD leading to hospitalisation are globally scarce.DesignObservational nationwide study using the French Programme de Médicalisation des Systèmes d’Information database.SettingFrance 2008–2013.ParticipantsAround 10 862 PLHIV out of a mean of 5 210 856 patients hospitalised each year. All hospital admissions with a main diagnosis code indicating KD (International Classification of Diseases, 10th revision codes, N00 to –N39) were collected.Main outcome measuresThe prevalence and incidenc…

AdultMalemedicine.medical_specialtyPediatricskidney diseasePopulation030232 urology & nephrology1842glomerular diseaseHIV InfectionsDiseaseacute renal failure03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)EpidemiologymedicinePrevalenceHumansCumulative incidence030212 general & internal medicine1506educationAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryhospitalisationIncidence (epidemiology)IncidenceResearchHIVGeneral MedicineMiddle Agedmedicine.diseaseHospitalizationHIV/AIDSObservational studyFemaleKidney DiseasesFrancebusinessKidney diseaseBMJ open
researchProduct

The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials

2021

Highlights • There is a need for reliable tools to predict the evolution of hospitalized patients suffering from COVID-19 • The likelihood of unfavourable evolution for patients hospitalized for COVID-19 with a National • Early Warning Score 2 (NEWS2) below 7 at Day 7 of hospitalization is nearly non-existent • Such a score could thus be used to allow earlier discharge of the patients and as a judgement criterion in therapeutic trials

0301 basic medicineMicrobiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNEWS2Communicable DiseasesArticle03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineUnfavourable eventAgedbusiness.industrySARS-CoV-2COVID-19Therapeutic trialCoronavirusHospitalizationInfectious DiseasesItalySARS-CoV2businessPredictionThe Journal of Infection
researchProduct

Detection of temporal clusters of health care-associated infections or colonizations with Pseudomonas aeruginosa.

2016

International audience; We investigated temporal clusters of Pseudomonas aeruginosa cases between 2005 and 2014 in 1 French university hospital, overall and by ward, using the Kulldorff method. Clusters of positive water samples were also investigated at the whole hospital level. Our results suggest that water outlets are not closely involved in the occurrence of clusters of P aeruginosa cases.

0301 basic medicinemedicine.medical_specialtyEpidemiology030106 microbiology030501 epidemiologymedicine.disease_causeHealth care associatedMicrobiologyHospitals University03 medical and health sciences[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicinemedicineCluster AnalysisHumansPseudomonas InfectionsCross InfectionPseudomonas aeruginosabusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthWaterHospital levelUniversity hospital3. Good healthInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyCarrier StatePseudomonas aeruginosaFranceWater Microbiology0305 other medical sciencebusiness
researchProduct

Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients

2013

Abstract Background Even though it has been suggested that antiretroviral therapy has an impact on severe hypovitaminosis D (SHD) in HIV infected patients, it could be speculated that the different levels of residual inflammation on HAART (Highly Active Anti Retroviral Therapy) could contribute to SHD and aggravate bone catabolism in these patients. Methods A cross-sectional study was carried out in an unselected cohort of 263 HIV infected outpatients consulting during Spring 2010. Clinical examinations were performed and medical history, food habits, sun exposure and addictions were collected. Fasting blood samples were taken for immunological, virological, inflammation, endocrine and bone…

MaleHIV InfectionsGastroenterologyBone remodeling0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesAntiretroviral Therapy Highly Active030212 general & internal medicineYoung adult0303 health sciencesUnivariate analysisHepatitis CMiddle Aged25-hydroxyvitamin D3. Good healthAntiretroviral therapy[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInfectious DiseasesCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemalemedicine.symptomInflammation MediatorsResearch ArticleAdultmedicine.medical_specialtyBone metabolismantiretroviral therapy;bone metabolism;HIV;inflammation;25-hydroxyvitamin DInflammationvitamin D deficiencyBone and Boneslcsh:Infectious and parasitic diseases03 medical and health sciencesYoung AdultInternal medicinemedicineHumansMedical historylcsh:RC109-216AgedInflammation030306 microbiologybusiness.industryHIVmedicine.diseaseVitamin D DeficiencyImmunologybusinessBiomarkersBMC Infectious Diseases
researchProduct

Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19?

2021

Highlights • Antibiotics were a main part of COVID-19 treatments during the first epidemic peak. • Bacterial coinfections seem to be rare, especially if no ICU transfer needed. • We studied the place of antibiotics and the impact on prognosis of patients. • Antibiotics were prescribed if more severe infection and has no impact on prognosis. • We think that antibiotic therapy must be not widely prescribed.

Male0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyAntibioticsInfectious and parasitic diseasesRC109-216Articlelaw.inventionHospitals University03 medical and health sciences0302 clinical medicinelawInternal medicinemedicineHumans030212 general & internal medicineMedical prescriptionPropensity ScoreAgedAged 80 and overUnivariate analysisbusiness.industrySARS-CoV-2Hazard ratioCOVID-19General MedicineMiddle AgedAntibiotic therapyPrognosisIntensive care unitConfidence intervalAnti-Bacterial AgentsCOVID-19 Drug TreatmentHospitalizationInfectious DiseasesRadiological weaponSARS-CoV2Propensity score matchingFemaleFrancebusinessInternational Journal of Infectious Diseases
researchProduct

Time to blood culture positivity: An independent predictor of infective endocarditis and mortality in patients with Staphylococcus aureus bacteraemia

2019

International audience; Objectives - Time to blood culture positivity (TTP), a routinely available parameter in automated blood culture systems, may be a proxy for infectious burden in patients with bloodstream infections. We aimed to study the association between TTP and infective endocarditis (IE), or death, in patients with Staphylococcus aureus bacteraemia. Methods - VIRSTA is a multicenter prospective cohort study that included all adult patients with S. aureus bacteraemia in eight university hospitals in France (2009-2011). We analyzed data from four centers which collected data on TTP. Regression models were used to study the association between TTP and definite IE (Duke-Li criteria)…

MaleMethicillin-Resistant Staphylococcus aureus0301 basic medicineMicrobiology (medical)Staphylococcus aureusbacteraemiamedicine.medical_specialtyTime FactorsMultivariate analysis030106 microbiologyBacteremiaIndependent predictormedicine.disease_cause03 medical and health sciences0302 clinical medicineInterquartile rangehemic and lymphatic diseasesInternal medicinemedicineHumansBlood cultureProspective Studies030212 general & internal medicinetime to blood culture positivityProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedmedicine.diagnostic_testinfective endocarditisbusiness.industryEndocarditis BacterialGeneral MedicineMiddle AgedStaphylococcal Infectionsrespiratory systemmedicine.diseasemortality3. Good health[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesQuartileBlood CultureStaphylococcus aureusInfective endocarditisFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyClinical Microbiology and Infection
researchProduct

Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study.

2013

Background Current recommendations for empirical antimicrobial therapy in spontaneous bacterial peritonitis (SBP) are based on quite old trials. Since microbial epidemiology and the management of patients have changed, whether these recommendations are still appropriate must be confirmed. Methods An observational study that exhaustively collected the clinical and biological data associated with positive ascitic fluid cultures was conducted in four French university hospitals in 2010–2011. Results Two hundred and sixty-eight documented positive cultures were observed in 190 cirrhotic patients (median age 61.5 years, 58.5% Child score C). Of these, 57 were classified as confirmed SBP and 140 …

MalePathologymedicine.medical_specialtyAntibiotic susceptibilitymedicine.drug_classEpidemiologyAntibioticsCephalosporinResistanceContext (language use)Microbial Sensitivity TestsPeritonitisAmoxicillin-Potassium Clavulanate CombinationAntibiotic resistanceMedical microbiologySpontaneous bacterial peritonitisAnti-Infective Agents[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyEpidemiologyDrug Resistance BacterialmedicineEscherichia coliSpontaneous bacterial peritonitisAscitic FluidHumans[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedCross Infection[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryBacterial InfectionsMiddle AgedAntimicrobialmedicine.disease3. Good healthAnti-Bacterial AgentsTreatment Outcome[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesBacterascitesFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Article
researchProduct

Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with external ventricular drain

2018

International audience; Background: Due to its antibacterial properties ceftaroline could be attractive for the treatment of bacterial postneurosurgicalmeningitis. However only few data are available concerning its meningeal concentrations. The aim of this studywas to investigate ceftaroline cerebrospinal fluid (CSF) pharmacokinetics (PK) in intensive care unit (ICU) patients with anexternal ventricular drain (EVD).Materials/methods: Patients received a single 600 mg dose of ceftaroline as a one-hour intravenous infusion . Blood and CSFsamples were collected before and 0.5, 1, 3, 6, 12 and 24 hours after the end of the infusion. Concentrations were assayed inplasma and CSF by LC-MS/MS. A tw…

[SDV] Life Sciences [q-bio][SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciencesICU patients[SDV]Life Sciences [q-bio]ceftaroline[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencespharmacokineticscerebrospinal fluid
researchProduct

Detection of Temporal Clusters of Healthcare-Associated Infections or Colonizations with Pseudomonas aeruginosa in Two Hospitals: Comparison of SaTSc…

2014

International audience; The identification of temporal clusters of healthcare-associated colonizations or infections is a challenge in infection control. WHONET software is available to achieve these objectives using laboratory databases of hospitals but it has never been compared with SaTScan regarding its detection performance. This study provided the opportunity to evaluate the performance of WHONET software in comparison with SaTScan software as a reference to detect clusters of Pseudomonas aeruginosa. A retrospective study was conducted in two French university hospitals. Cases of P. aeruginosa colonizations or infections occurring between 1st January 2005 and 30th April 2014 in the fi…

Male[SDE] Environmental Scienceslcsh:MedicineInfection controlmedicine.disease_causeDisease OutbreaksHospitals University0302 clinical medicineSoftware[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyCluster AnalysisInfection controlSoftware toolsPoisson Distribution030212 general & internal medicinelcsh:ScienceCross InfectionMultidisciplinaryIncidenceIncidence (epidemiology)University hospital3. Good healthMonte Carlo method[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyWater pollutionPseudomonas aeruginosa[SDE]Environmental SciencesFemaleResearch ArticleHealthcare associated infectionsmedicine.medical_specialtyPermutation030231 tropical medicineMicrobiology03 medical and health sciencesNosocomial infectionsmedicineHumansPseudomonas InfectionsIntensive care medicineUnit levelAgedRetrospective StudiesPseudomonas aeruginosabusiness.industrylcsh:RBacteriologyRetrospective cohort study[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieEmergency medicinelcsh:Q[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessSoftware
researchProduct

Auswirkungen eines neuen Wassersystems auf nosokomiale Kolonisierung oder Infektion mit Pseudomonas aeruginosa

2016

Aim: We aimed to study the impact of new water systems, which were less contaminated with P. aeruginosa, on the incidence of healthcare-associated P. aeruginosa cases (colonizations or infections) in care units that moved to a different building between 2005 and 2014. Methods: Generalized Estimated Equations were used to compare the incidence of P. aeruginosa healthcare-associated cases according to the building. Results: Twenty-nine units moved during the study period and 2,759 cases occurred in these units. No difference was observed when the new building was compared with older buildings overall. Conclusion: Our results did not support our hypothesis of a positive association between wat…

0301 basic medicinelcsh:Public aspects of medicineTrinkwassersystem030106 microbiologylcsh:Rlcsh:QR1-502lcsh:Medicinelcsh:RA1-1270030501 epidemiology610 Medical sciences; Medicineinfection controllcsh:MicrobiologyArticlenosokomiale Infektionen3. Good healthInfektionskontrolle03 medical and health sciences[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseaseswater systemshealthcare-associated infectionsddc: 610[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesNosocomial infectionsPseudomonas aeruginosa0305 other medical scienceGMS Hygiene and Infection Control
researchProduct